{
 "query": "triptorelin",
 "ingredient": "triptorelin",
 "slug": "triptorelin",
 "rxcui": "38782",
 "brands": [
  "Triptodur"
 ],
 "names": [
  "triptorelin",
  "triptorelin acetate",
  "triptorelin pamoate"
 ],
 "classes": [
  {
   "id": "L02AE",
   "name": "Gonadotropin releasing hormone analogues"
  }
 ],
 "alternatives": [
  "buserelin",
  "goserelin",
  "histrelin",
  "leuprolide"
 ],
 "label": {},
 "faers": {
  "total": 7307,
  "serious": 5122,
  "death": 822,
  "hospitalization": 2056,
  "primary_suspect": 7282,
  "top_reactions": [
   [
    "Off Label Use",
    613
   ],
   [
    "Death",
    496
   ],
   [
    "Ovarian Hyperstimulation Syndrome",
    405
   ],
   [
    "Needle Issue",
    246
   ],
   [
    "Fatigue",
    238
   ],
   [
    "Disease Progression",
    222
   ],
   [
    "Drug Ineffective",
    217
   ],
   [
    "Hot Flush",
    216
   ],
   [
    "Asthenia",
    204
   ],
   [
    "Product Dose Omission Issue",
    204
   ],
   [
    "Headache",
    192
   ],
   [
    "Nausea",
    182
   ],
   [
    "Weight Increased",
    173
   ],
   [
    "Malignant Neoplasm Progression",
    162
   ],
   [
    "Inappropriate Schedule Of Product Administration",
    157
   ]
  ],
  "by_year": {
   "2019": 1107,
   "2020": 749,
   "2021": 730,
   "2022": 634,
   "2023": 683,
   "2024": 703,
   "2025": 886,
   "2026": 435
  },
  "by_year_primary": {
   "2019": 1107,
   "2020": 749,
   "2021": 719,
   "2022": 633,
   "2023": 680,
   "2024": 702,
   "2025": 878,
   "2026": 434
  }
 },
 "faers_base": {
  "total": 20692304,
  "serious_share": 0.5742697381596559,
  "death_share": 0.09102355155810585
 },
 "recalls": [],
 "recall_total": 0,
 "drugsfda": {
  "applications": 4,
  "nda": 4,
  "anda": 0,
  "first_approval": "20000615",
  "rems": false,
  "rems_last": "",
  "labeling_supplements": 43,
  "labeling_recent": 21,
  "sponsors": [
   "AZURITY",
   "VERITY"
  ],
  "unapproved": false,
  "first_approval_fmt": "06/15/2000"
 },
 "trials": {
  "total": 298,
  "completed": 125,
  "terminated": 27,
  "with_results": 48,
  "industry": 76,
  "phase3": 86,
  "results_share": 0.384,
  "terminated_share": 0.09060402684563758
 },
 "pubmed": {
  "rct": 56,
  "meta": 2,
  "recent_rct": 7,
  "cochrane": []
 },
 "payments": {
  "year": "2024",
  "usd": 23064.71,
  "records": 677,
  "by_name": [
   [
    "Triptodur",
    23064.71
   ]
  ],
  "names_checked": [
   "triptorelin",
   "Triptodur"
  ],
  "source": "bulk-index"
 },
 "partd": {
  "year": "2024",
  "claims": 6223,
  "beneficiaries": 2414,
  "spend": 15333167.35,
  "by_brand": [
   {
    "brand": "Trelstar",
    "claims": 6223,
    "per_claim": 2463.9510445,
    "is_generic": false
   }
  ],
  "per_claim": 2463.9510445122933
 },
 "mdl": [],
 "dsc": [],
 "settlements": [],
 "prescrire": null,
 "eml": {
  "listed": true,
  "status": "AddedToEml",
  "name": "triptorelin",
  "matched": "triptorelin",
  "stewardship": []
 },
 "exposure": null,
 "scores": {
  "safety": {
   "score": 95,
   "letter": "A",
   "why": [
    "Death share in reports is near or below the FAERS average (1.2x)",
    "Off-label use is among the five most-reported items: widely used beyond its approved evidence (-5)"
   ],
   "weight": 0.35
  },
  "evidence": {
   "score": 35,
   "letter": "F",
   "why": [
    "56 randomized trials and 2 systematic reviews/meta-analyses indexed in PubMed",
    "On the WHO Model List of Essential Medicines (shown for context; no score effect)",
    "No Cochrane review found (-5)",
    "Only 38% of completed registered trials posted results (-8)"
   ],
   "weight": 0.25
  },
  "regulatory": {
   "score": 92,
   "letter": "A",
   "why": [
    "No recalls on record since 2016",
    "21 label changes approved since 2021: the safety story is still moving (-8)"
   ],
   "weight": 0.15
  },
  "conflict": {
   "score": 100,
   "letter": "A",
   "why": [
    "Pharma paid doctors $23,065 tied to this drug last year: negligible",
    "Not named in any pending federal MDL"
   ],
   "weight": 0.15
  },
  "options": {
   "score": 70,
   "letter": "C",
   "why": [
    "No generic version approved: brand-only pricing (-30)",
    "4 same-class alternatives exist"
   ],
   "weight": 0.1
  }
 },
 "total": 78,
 "grade": "B",
 "questions": [
  "The most-reported problems in FDA's adverse event data are death, ovarian hyperstimulation syndrome, needle issue. How would we recognize and handle those?",
  "Off-label use is among the most-reported items for this drug. Is my use on-label, and if not, what evidence supports it?",
  "Why this one over buserelin, goserelin, histrelin? What would make you pick one of those instead?",
  "There is no generic. Is there an older generic in the same class that works as well for my situation?",
  "What result are we expecting, by when, and what is the plan if it does not happen?",
  "If 100 people like me took this drug, how many would actually get better because of it, and how many would be harmed by it? (Doctors call these the number needed to treat and the number needed to harm.)"
 ]
}